Historical record - last NADAC effective date: 6/17/2015
Product Information
AMLODIPINE-BENAZEPRIL 5-20 MG is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.3238 per EA under NDC 68180075702. Its NADAC has been published 86 times since Nov 28, 2013.
FDA first approved this application on Feb 5, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 20 mg/1; mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180075702
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
6/17/2015
Active Ingredients
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078466FDA Approved
2/5/2010
TE Code
AB
On Market Since
2/5/2010
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has been published 86 times since Nov 28, 2013, and over the history we have for it it has declined 31.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3238 per EA |
|---|---|
| All-time high | $0.4743 (Dec 11, 2013) |
| All-time low | $0.3238 (Jun 17, 2015) |
| Median price | $0.3657 |
| Average price | $0.3763 |
| Largest weekly change | -17.1% (Feb 18, 2015) |
| Weeks tracked | 86 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-31.7%
Last surveyed Jul 15, 2015 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 68% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine Besylate and Benazepril Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-BENAZEPRIL 5-20 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-BENAZEPRIL 5-20 MG, manufactured by Lupin Pharmaceuticals Inc., is $0.3238 per EA (NDC 68180075702), effective Jul 15, 2015.
How has the price of AMLODIPINE-BENAZEPRIL 5-20 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has declined 31.7%. It has been tracked across 86 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-BENAZEPRIL 5-20 MG?
Since Nov 28, 2013, the NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has ranged from a low of $0.3238 (Jun 17, 2015) to a high of $0.4743 (Dec 11, 2013), with a median of $0.3657 per EA.
Are there cheaper alternatives to AMLODIPINE-BENAZEPRIL 5-20 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AMLODIPINE-BENAZEPRIL 5-20 MG, is $0.1035 per EA — about 68% below AMLODIPINE-BENAZEPRIL 5-20 MG.
Who manufactures AMLODIPINE-BENAZEPRIL 5-20 MG?
AMLODIPINE-BENAZEPRIL 5-20 MG (NDC 68180075702) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.